Clinical evaluation of Lomefloxacin (LFLX) in oral infection treatment

Abstract

We studied the usefulness of Lomefloxacin in the field of oral surgery at 11 institutions in Tokyo. The subjects were 83 patients with periodontitis, 86 patients with pericoronitis, and 69 patients with osteitis of the jaw. Iifferent doses of the drug were administered depending on the institution, with 118 patients receiving 400 mg/day and 120 patients receiving 600 mg/day.
In the 234 patients suitable for analysis, there was a clinical improvement rate of 81.3 % for periodontitis (marked improvement in 26 cases and improvement in 39 cases), 79.1 % for pericoronitis (marked improvement in 21 cases and improvement in 47 cases), and 83.8 % for osteitis of the jaw (marked improvement in 19 cases and improvement in 38 cases) . The efficacy rate was 83.8 % for periodontitis, 86 % for pericoronitis, and 88.2 % for osteitis of the jaw. Gram-positive bacteria accounted for 63.0 % of the isolated bacteria. Adverse reactions and abnormal laboratory test values were noted in 4 patients, but were mild to moderate in severity.
When administration was discontinued, the usefulness rating was “very useful” in 67 patients, “useful” in 121 patients, and “slightly useful” in 28 patients. The “useful” or better rate was 81.3 % in patients having periodontitis, 79.1 % in those having pericoronitis, and 80.9 % in those having osteitis of the jaw. There were no significant differences between the results obtained by using doses of 400 mg/day and 600 mg/day.